<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0">
<channel>
	<title>BioToday.com [新着ニュース]</title>
	<description>BioToday.comは医学情報、バイオテクノロジー、バイオベンチャー関連ニュースのデータベースです。</description>
	<link>http://www.biotoday.com/news.cfm</link>
	<managingEditor>biotoday@biotoday.com</managingEditor>
	<copyright>Copyright &#169; 2026 BioToday Ltd. All Rights Reserved.</copyright>
	<lastBuildDate>Tue, 06 Oct 2026 16:30:03 +0900</lastBuildDate>
	<language>ja</language>
	<docs>http://blogs.law.harvard.edu/tech/rss</docs>
	<item>
		<title>[企業] 抗炎症/線維化のAlentis社の抗クローディン1抗体lixudebartにCSLが協力する</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110803&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110803&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 企業間提携</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 06 Oct 2026 16:29:57 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110803&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] LillyがGate社との提携に標的を1つ追加</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110802&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110802&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 企業間提携</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 06 Oct 2026 15:12:50 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110802&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Alector社の脳に届くグルコセレブロシダーゼ補充薬の権利をRocheが取得</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110801&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110801&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / ライセンス</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 06 Oct 2026 12:59:11 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110801&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 50歳以上成人へのVaxcyte社の31価肺炎球菌ワクチンVAX-31のPh3試験目標達成</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110800&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110800&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 06 Oct 2026 11:53:17 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110800&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 塩野義製薬がIntraBio社を買って神経変性疾患薬Aqneursaを手に入れる</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110799&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110799&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 合併/買収</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 06 Oct 2026 10:09:26 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110799&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] アバメタピルとフラベソンの1回きり全身塗布がダニ寄生皮膚病の疥癬ブタに有効</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110798&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110798&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 06 Oct 2026 09:45:57 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110798&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 頭蓋骨髄からの単球が外傷性脳損傷後の神経炎症を促す</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110797&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110797&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 06 Oct 2026 08:52:56 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110797&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 多くを死なす菌血症を引き起こすMRSAが腎髄質内層にたむろすると判明</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110796&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110796&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 06 Oct 2026 08:30:50 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110796&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 米国第3代大統領Thomas Jeffersonが奴隷との間に子をもうけたことはかなり確実</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110795&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110795&amp;ref=rss</guid>
		<category>技術 / 診断 / 全般</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Mon, 05 Oct 2026 16:46:08 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110795&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] アルツハイマー病患者の脳のもつれたタウが他のタウも同様にもつれさせる</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110794&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110794&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Mon, 05 Oct 2026 16:01:28 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110794&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] GATA2欠損症の遺伝子変異を効率よく安全に正すDSB不要プライム編集法開発</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110793&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110793&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Mon, 05 Oct 2026 13:06:25 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110793&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 神経を胎盤膜で包むことで前立腺癌手術後の勃起を助ける</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110792&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110792&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Mon, 05 Oct 2026 10:58:17 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110792&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 1つの眉唾な小試験結果が小児の抗うつ薬プロザック使用を有益へと傾けた</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110791&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110791&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / その他臨床試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 04 Oct 2026 16:31:07 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110791&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 脳卒中がカルシウム伝達低下アストロサイトを発生させて神経膠腫を増やす</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110790&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110790&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 04 Oct 2026 15:47:07 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110790&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 運動はmicroRNA-29豊富な細胞外小胞を介して軟骨細胞を若返らせる</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110789&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110789&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 04 Oct 2026 14:08:24 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110789&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] Verastem社のRAF/MEK縛り付け薬+FAK阻害薬併用がKRAS G12C阻害薬を助ける</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110788&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110788&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 04 Oct 2026 13:39:13 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110788&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 免疫や代謝へのプラスチック粒の大きさ毎の影響が判明</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110787&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110787&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 04 Oct 2026 12:20:55 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110787&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] AstraZenecaの異議でHansoh社のEGFR阻害薬Aumseqaの承認を欧州が取り消し</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110786&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110786&amp;ref=rss</guid>
		<category>ビジネス / 会社運営 / 販売中止</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 04 Oct 2026 10:35:12 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110786&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Pfizerの経口JAK阻害薬Litfuloの目標達成した白斑Ph3試験2つの結果詳細</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110785&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110785&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 04 Oct 2026 09:57:39 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110785&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 米国の新会社Somniveraが臨床試験段階の睡眠障害薬の中国外権利を取得</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110784&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110784&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / ライセンス</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 04 Oct 2026 09:28:52 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110784&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 体内でT細胞差し向け薬を作る自己免疫疾患治療をNovartisがAbogen社から取得</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110783&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110783&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 企業間提携</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 04 Oct 2026 08:33:59 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110783&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] LillyがFoghorn社とのSMARCA2標的薬提携打ち切り</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110782&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110782&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 企業間提携</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sat, 03 Oct 2026 16:34:04 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110782&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 未治療の非肝硬変慢性HCV患者のsofosbuvir/velpatasvir投与8週間が12週間に比肩</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110781&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110781&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / Lancet</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sat, 03 Oct 2026 14:07:41 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110781&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] Lillyの経口GLP-1薬Foundayoの糖尿病治療の取り柄を示したPh3試験結果詳細</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110780&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110780&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sat, 03 Oct 2026 12:20:35 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110780&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] PfizerのIL-4/IL-13/TSLP抗体tilrekimigのアトピー性皮膚炎Ph2試験結果詳細</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110779&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110779&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第2相試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sat, 03 Oct 2026 09:45:35 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110779&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 2型糖尿病患者の肥満をBI社のsurvodutideで治療したPh3試験で体重が10%弱低下</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110778&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110778&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / New England Journal of Medicine（NEJM）</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 02 Oct 2026 15:14:01 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110778&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] SanofiがRegeneronとの提携を拡大して長く効く抗体4つの開発と販売に協力する</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110777&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110777&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 企業間提携</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 02 Oct 2026 14:19:50 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110777&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Regeneron社のtrevogrumab低用量もGLP-1薬の筋肉減少を抑制</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110776&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110776&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第2相試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 02 Oct 2026 12:57:36 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110776&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] Lillyの3G薬retatrutideが肥満成人の体重を多ければ4分の1減らしたPh3試験論文</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110775&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110775&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / New England Journal of Medicine（NEJM）</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 02 Oct 2026 11:19:35 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110775&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 心血管疾患/糖尿病/認知症を経ていない高齢者の心血管一大事がスタチンで減る</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110774&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110774&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / New England Journal of Medicine（NEJM）</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 02 Oct 2026 09:59:41 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110774&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] Rocheのgiredestrantで進行乳癌患者の無増悪生存が改善したPh3試験結果論文</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110773&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110773&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / New England Journal of Medicine（NEJM）</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 01 Oct 2026 16:28:00 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110773&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 円板状エリテマトーデス患者の重症度がAmgenの抗ILT7抗体でプラセボ比6点低下</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110772&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110772&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第2相試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 01 Oct 2026 14:42:02 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110772&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 化膿性汗腺炎患者の多ければ7割超がMerck &amp; Coの抗TL1A抗体でHiSCR50達成</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110771&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110771&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第2相試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 01 Oct 2026 12:59:44 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110771&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] Roche/Zealandのアミリンの類いpetrelintideの体重低下が中用量で頭打ち</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110770&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110770&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / Lancet</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 01 Oct 2026 12:17:14 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110770&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Lillyの肥満薬2つ組み合わせEloraTZPで体重がより減少〜今年中にPh3試験開始</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110769&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110769&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第2相試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 01 Oct 2026 11:48:12 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110769&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Vanda社のメラトニン受容体活性化薬の睡眠-覚醒相後退障害のPh3試験目標達成</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110768&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110768&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 01 Oct 2026 10:00:47 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110768&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Rocheの多発性硬化症薬fenebrutinib承認申請を米国受理</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110767&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110767&amp;ref=rss</guid>
		<category>開発 / 承認申請 / 承認申請</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 01 Oct 2026 08:19:55 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110767&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 過敏性腸症候群に糞中微生物移植（FMT）無益</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110766&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110766&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / Lancet</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 01 Oct 2026 08:04:15 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110766&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 異型髄膜腫の手術切除後の照射で無再発生存が改善</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110765&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110765&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / Lancet</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 30 Sep 2026 16:25:38 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110765&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] Regeneronの抗ActA抗体PasatruがFOP患者の新規異所骨を減らしたPh3試験論文</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110764&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110764&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / Lancet</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 30 Sep 2026 15:47:06 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110764&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 肥えている2型糖尿病患者の体重がLillyの3G薬retatrutideで多ければ2割弱減少</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110763&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110763&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / Lancet</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 30 Sep 2026 14:43:23 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110763&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 自己免疫疾患を治療するTh17細胞除去薬を開発するai3Bio社が5千万ドル弱調達</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110762&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110762&amp;ref=rss</guid>
		<category>ビジネス / ファイナンス / 投資/融資</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 30 Sep 2026 14:26:05 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110762&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] uniQure社のハンチントン病遺伝子治療の病状進行遅延効果が4年時点で見られず</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110761&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110761&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第2相試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 30 Sep 2026 13:22:41 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110761&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] タウ蓄積で脳が傷むのをT細胞通行を止めるCXCR3阻害で減らしうる</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110760&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110760&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 30 Sep 2026 11:55:15 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110760&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] ヌクレオチドの類いのkamuvudine-9で多発性硬化症のマウスの麻痺と失明が解消</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110759&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110759&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 30 Sep 2026 10:09:17 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110759&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 癌の軟膜髄膜転移の増殖をCxcr2遮断薬で阻止しうる</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110758&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110758&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 30 Sep 2026 09:32:15 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110758&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] Breye社のギャップ結合調節薬danegaptideが糖尿病網膜症Ph1b試験を恙無く通過</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110757&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110757&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 30 Sep 2026 08:40:40 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110757&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Adicet社のCD20標的γδT細胞で全身性エリテマトーデス患者の54%が1年時点寛解</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110756&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110756&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第1相試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 30 Sep 2026 07:36:48 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110756&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Mirum社のD型肝炎ウイルス（HDV）薬brepocitinibのPh3試験目標達成</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110755&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110755&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 29 Sep 2026 17:04:59 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110755&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Kodiak社の長く効く抗VEGF抗体がwAMDのPh3試験でRegeneronのEyleaに比肩</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110754&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110754&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 29 Sep 2026 16:30:55 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110754&amp;ref=rss</comments>
	</item>
</channel>
</rss>
